All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Monoclonal antibodies target antigens expressed predominantly by leukemic cells, making them more selective than chemotherapy. Antibodies induce an immune response to destroy cancer cells, or block key extracellular sites such as receptors to induce cancer cell death. The therapeutic potential of targeting CD19, CD22, or CD33 might vary according to age and ALL subtype.